Last updated on March 2019

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis


Brief description of study

This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.

Detailed Study Description

This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and psoriasis.

Subjects will be queried regarding adverse events (AEs) and concomitant medication usage.

Clinical Study Identifier: NCT03381625

Contact Investigators or Research Sites near you

Start Over

Cynthia Strout, MD

Coastal Carolina Research Center
Mount Pleasant, SC United States
1.13miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.